Essential Thrombocythemia: JAK Kinase Mutations Are Pathogenetically Associated
The correct answer is C: Essential thrombocythemia may be associated with JAK kinase mutations. Approximately 64% of ET patients harbor JAK2 mutations, 23% have CALR mutations, and 4% have MPL mutations—all of which upregulate the JAK-STAT signaling pathway 1, 2.
Analysis of Each Statement
A) Philadelphia Chromosome Association - FALSE
The Philadelphia chromosome (BCR-ABL1) is explicitly excluded in the diagnostic criteria for essential thrombocythemia. ET is classified as a Philadelphia chromosome-negative myeloproliferative neoplasm 1, 3. The WHO 2016 diagnostic criteria specifically require "not meeting WHO criteria for BCR-ABL1+ CML" to diagnose ET 1. This distinguishes ET from chronic myeloid leukemia, which is defined by the Philadelphia chromosome.
B) Severe Iron Deficiency as a Cause - FALSE
Iron deficiency anemia causes reactive (secondary) thrombocytosis, not essential thrombocythemia 4, 2. ET is a clonal myeloproliferative neoplasm with specific diagnostic criteria including bone marrow morphology showing megakaryocyte proliferation with large, mature morphology and the presence of driver mutations (JAK2, CALR, or MPL) 1. Iron deficiency must be excluded when evaluating thrombocytosis, as it represents a secondary cause that resolves with treatment of the underlying condition 4.
C) JAK Kinase Mutations - TRUE
Approximately 90% of ET patients have genetic variants that upregulate the JAK-STAT signaling pathway 2. The WHO 2016 diagnostic criteria include "presence of JAK2, CALR, or MPL mutation" as a major criterion for ET diagnosis 1. The specific breakdown is:
- JAK2 mutations: 64%
- CALR mutations: 23%
- MPL mutations: 4%
- Triple-negative (no driver mutation): ~10%
JAK2V617F mutation is also associated with increased thrombosis risk and should influence risk stratification 5, 2.
D) Hemorrhagic Manifestations - FALSE
ET can definitely be associated with hemorrhagic complications. Hemorrhagic events occur in approximately 8% of patients with ET 2. The disease paradoxically causes both thrombotic and bleeding complications 5, 6. Hemorrhage risk is particularly elevated with extreme thrombocytosis and requires specific management strategies 5. The clinical consequences of uncontrolled thrombocytosis include both thrombosis and hemorrhage 7.
E) Interferon as First-Line Treatment - FALSE
Hydroxyurea is the first-line cytoreductive agent for essential thrombocythemia 5, 4. While pegylated interferon-α is considered a first-line option alongside hydroxyurea 5, it is not the first-line treatment. The treatment hierarchy is:
- Low-dose aspirin (81-100 mg/day) for most patients to reduce thrombosis risk 2
- Hydroxyurea as first-line cytoreductive therapy for high-risk patients 5, 4
- Pegylated interferon-α as an alternative first-line cytoreductive option 5
- Busulfan as second-line therapy 5
A randomized trial (PROUD-PV) showed PEG-proline-IFN-alpha-2b had non-inferior efficacy to hydroxyurea with higher tolerability 1, but this doesn't establish interferon as the first-line treatment universally.
Key Clinical Pearls
Risk stratification determines treatment intensity:
- Very low risk: age ≤60 years, no thrombosis history, JAK2 wild-type
- Low risk: same as very low but JAK2 mutation present
- Intermediate risk: age >60 years with JAK2 mutation
- High risk: thrombosis history or age >60 years with JAK2 mutation 5
Cytoreductive therapy is indicated for high-risk disease and optional for intermediate-risk disease 5. In a randomized trial of 114 high-risk patients, hydroxyurea significantly reduced thrombotic events compared to no cytoreduction (3.6% vs 24%; P < .01) 2.